期刊文献+

血清FPSA/TPSA及性腺激素测定结合核素骨显像在前列腺癌诊断、复发和转移中的临床价值 被引量:5

Evaluation of serum FPSA/TPSA and hormone determination combinded with nuclide bone imaging in diagnosis of prostate carcinoma and its recidivation and metastasis
原文传递
导出
摘要 目的探讨血清游离前列腺特异抗原(FPSA)、总前列腺特异抗原(TPSA)、FPSA/TPSA比值、血清催乳素、促卯泡激素(FSH)、促黄体激素(LH)、雌二醇、孕酮、睾酮的测定并结合^99Tc^m—MDP全身骨显像在前列腺癌诊断、前列腺良恶性疾病鉴别诊断及前列腺癌转移和复发中的临床价值。方法采用罗氏电化学发光分析法测定44名健康男性、75例良性前列腺疾病[其中41例良性前列腺增生(BPH)、25例BPH伴急性尿潴留(BPH+AUR)者,9例急性前列腺炎(AP)1和48例经病理证实的前列腺癌患者血清催乳素、FSH、LH、雌二醇、孕酮、睾酮及TPSA、FPSA、FPSA/TPSA测定。用^99Tc^mMDP对48例前列腺癌患者进行全身骨显像,分析各项指标对前列腺疾病诊断、鉴别诊断的临床价值。结果①前列腺癌及良性前列腺疾病患者TPSA、FPSA明显高于正常对照组(t1=11.42,t2=12.01,P〈0.01);②前列腺癌患者TPSA、FPSA明显高于良性前列腺疾病组(t1=10.69,t2=11.18,P〈0.01);⑧前列腺癌患者FPSA/TPSA比值明显低于BPH组(t=2.95,P〈0.01),但与BPH+AUR组及AP组之间无明显差异(t1=0.73,t2=0.62,P〉0.05)。④前列腺癌患者FSH、LH明显高于良性前列腺疾病组及正常对照组,睾酮低于正常对照组和BPH组,而其他性腺激素催乳素、雌二醇、孕酮无显著差异(P〉0.05);⑤前列腺癌不同治疗方案的选择在治疗前后除根治术外,其他各组治疗前后FSH、LH、睾酮均有明显变化(FSH:t=4.01,P〈0.01,LH:t=2.46,P〈0.05;睾酮:t=3.20,P〈0.01);⑥有骨转移的前列腺癌患者TPSA、FPSA显著高于未发生骨转移者(tTPSA=5.38,TFPSA=4.26,P〈0.01),但FPSA/TPSA比值两者之间无显著差异(t=1.61,P〉0.05)。结论TPSA、FPSA在诊断前列腺癌、鉴别前列腺癌与良性前列腺疾病及判断骨转移等方面有着重要的临床价值;FPSA/TPSA〈0.16时前列腺癌发生的风险将增大,但不能独立用于诊断前列腺癌,TPSA、FPSA和陛晾澈刹4定结合^99Tc^m-MDP全身骨显像对于前列腺癌的诊断、疗效观察和判断复发与转移有着重要的临床价值。 Objective To evaluate the clinical value of free prostate antigen (FPSA) , total prostate specific antigen (TPSA) , FPSA / TPSA and serum hormones (PRL, FSH, LH, Prog, T, E2) combined with ECT bone imaging in patients with prostate carcinoma. Methods 44 healthy males, 75 patients of benign prostate disease (including 41 of benign prostatic hyperplasia (BPH) and 25 of HBP with acute urinary retention (BPH + AUR) surgery, 9 of acute prostatitis) , and 48 patients with prostate carcinoma were enrolled in this study. Their Gonadal hormones and TPSA, FPSA, FPSA / TPSA were measured. Results (1) The level of TPSA and FPSA in patients with prostate carcinoma or benign prostate disease were significantly higher than in healthy control (t1=11.42, t2=12.01, P〈0.01 ); (2)Those in patients with prostate careinoma were obviously higher than in patients with benign prostate disease (t1=10.69, t2=l 1.18, P〈0.01 ); (3)The ratio of FPSA/TPSA in patients with prostate carcinoma was obviously lower than those with BPH (t1=10.69, t2=11.18, P〈0.01 ), but there were no significant differences between patients with BPH +AUR and acute prostatitis (t1=0.73, t2 =0.62, P〉0.05 ); (4)The FSH and LH of gonadal hormones in patients with prostate carcinoma were obviously higher than in patients with benign prostate diseases and healthy control. (4) Except patients having operation total correction, the gonadal hormones and FSH/LH, T in patients with prostate carcinoma having different treatment programs all had variances before and after therapy; (5)TPSA and FPSA in patients with prostate carcinoma having bone metastasis were much higher than those without bone metastasis (tTPA =5.38, tFPSA =4.26, P〈0.01 ), the ratio of FPSA/TPSA between those two had no significant disparity (t=1.61, P〉0.05). Conclusion here was great clinlical value of the determination of TPSA and FPSA in diagnosis of prostate carcinoma, identification of prostate carcinoma and benign prostate disease and in judgment of bone metastasis. The ratio of FPSA/TPSA 〈0.16 is a proper prediction index for diagnosis of prostate carcinoma, FPSA /TPSA might be 〈0.16 in healthy ones and patients with acute prostatitis or BPH ; but when FPSA / TPSA 〈0.16, the risk of prostate cancer would increase; Gonadal hormones is useful biomarkem in diagnosis and treatment in patients with prostate carcinoma.
出处 《国际放射医学核医学杂志》 2010年第6期337-343,共7页 International Journal of Radiation Medicine and Nuclear Medicine
基金 湖北省卫生厅科研基金项目(JX3852)
关键词 前列腺肿瘤 前列腺特异抗原 性腺激素类 99M锝美罗酸盐 Prostatic neoplasms Prostate specific antigen Gonadal hormones Techmetium Tc 99m Medronate
  • 相关文献

参考文献14

  • 1宋刚,周利群,那彦群.血清PSA与前列腺癌分级、分期的关系[J].国际泌尿系统杂志,2006,26(2):219-222. 被引量:4
  • 2李跃进,李登清,谭湘芳,方勇.血清T-PSA、F-PSA水平和F/T比值与前列腺癌病理分级的相关性[J].实用预防医学,2007,14(2):344-345. 被引量:2
  • 3Catalona WJ, Partin AW, Stawin KM, et al. Use of percentage of free prastate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective mnhicenter clinical trial, JAMA, 1998, 279: 1542-1547.
  • 4Ornstein DK, Rao GS, Smith DS, et al. Effect of digital rectal examination and needle biopas on serum total and percentage of free prostate specific antigen levels. J Urol, 1997, 157(1): 195- 198.
  • 5Ciatto S, Bonardi R, Lombardi C, et al. predicting prostate biopsy outcome by findings at digital rectal examintion,transrectal uhrasonograply PSA, PSA density and free-to total PSA ratio in a popcilationbased screening setting. Int Biol Markers, 2001, 16(3): 179-182.
  • 6Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer, 2004, 101:2371 - 2490.
  • 7Hsing AW. Hormones and prostate cancer: what's next?, Epidemiol Rev, 2001, 23(1): 42-58.
  • 8Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Bioehem Mol Biol, 2004, 92 : 237-253.
  • 9Thompson IM, Goodman PJ, Tangen CM, et al. The infl uence of fi nasteride on the development of prostate cancer. N Engl J Med. 2003, 349: 215-224.
  • 10Canby-Hagino E, Henaandez J, Brand TC, et al. Looking back at PCPT: looking forward to new paradigms in prostate cancer screeningand prevention. Eur Urol, 2007, 51(1): 27-33.

二级参考文献45

  • 1夏同礼,邓方明,冯陶.血清前列腺特异性抗原增高的病理基础[J].中华医学杂志,1994,74(5):306-308. 被引量:22
  • 2杨友,韩丹,赵川,金树珍,吕绍茂.血清PSA与前列腺癌病理分级的相关性[J].现代泌尿外科杂志,2006,11(4):200-202. 被引量:11
  • 3鲍镇美,中华泌尿外科杂志,1997年,18卷,315页
  • 4梅骅,中华泌尿外科杂志,1997年,18卷,119页
  • 5郑思竞,系统解剖学(第3版),1989年,250页
  • 6Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate- specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi - institutional update. JAMA, 1997, 277:1445 - 1451.
  • 7Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer stanging nomograms ( Partin tables) for the new millennium. Urol, 2001,58:843- 848.
  • 8Roach M Ⅲ, Marquez C, Yuo H - S, et al. Predicting the risk of lymph node involvement using the pro - treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys, 1994, 28:33 - 37.
  • 9Roach M Ⅲ, Chen A, Song J, et al. Pretreatment prostate - specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients withclinically localized prostate cancer. Semin Urol Oneol, 2000, 18;108 - 114.
  • 10Papsidero LD, Kuriyama M, Wang M, et al. Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst, 1981,66:37 - 42.

共引文献34

同被引文献64

  • 1华立新,吴宏飞,眭元庚,徐正铨,张炜,钱立新,殷长军,居小兵,张杰秀.药物去势和手术去势对前列腺癌患者性激素的影响[J].中华泌尿外科杂志,2005,26(12):812-815. 被引量:12
  • 2张军,吕朝晖,母义明,潘长玉.前列腺癌患者性激素与促性腺激素的变化[J].中国实用内科杂志:临床前沿版,2006,26(7):1053-1055. 被引量:4
  • 3侯龙敏,谢有兰.前列腺癌骨转移患者血清PSA测定的临床价值[J].河南大学学报(医学版),2007,26(2):70-71. 被引量:4
  • 4Lemer SE,facobsen SJ,Lilja H,et al.Free,complexed,and total serum prostate-specific antigen concentration and their proportions in predicting stage,grade,and deoxyribo,conucleic acid ploidy in patients with adenocarcinoma of the prostate[J].Urology,1996,48(2):240-248.
  • 5Yang CR,Su CK,Chiu KY,et al.Free/total prostate specific antigen ratio for prostate cancer detection:a prospective blind study[J].Anticancer Res,2005,25(3):2439-2443.
  • 6Denmeade SR,Lsaacs JT.The role of prostate-specific antigen in the clinical evaluation of prostatic disease[J].BJU Int,2004,93(Suppl 1):10-15.
  • 7Stenman UH.A complex between prostate-specific antigen and antichymotrypsin is the major form of prostate cancer:assays of the complex improves the clinical sensitivity for cancer[J].Cancer Res,1991,51(1):222-226.
  • 8Bigler SA,Deering RE,Brawer MK.Comparison of microscopic vascularity in benign and malignant prostate tissue[J].Hun pathol,1993,24(2):220-225.
  • 9Stege RH,Tribukait B,Carlstrom KA,et al.Tissue PSA from fine-needle biopsyes of prostafic carcinoma as related to serun PSA,clinical stage,cytologyical grade,and DNA ploidy[J].Prostate,1999,38(3):183-188.
  • 10Ciatto S,Bonardi R,Lombardi C,et al.predicting prostate biopsy outcome by findings at digital rectal examintion,transrectal ultrasonograply PSA,PSA density and free-to total PSA ratio in a popcilationbased screening setting[J].Int Biol Markers,2001,16(3):179-182.

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部